Key result
Dapagliflozin is linked to ~26% lower UACR at 12 months compared to standard therapy.
Why the study?
Despite adequate glycemic control, many patients with T2DM and CKD continue to experience progressive renal dysfunction and adverse cardiovascular outcomes, necessitating evaluation of dapagliflozin's cardiorenal effects.
Does dapagliflozin 10 mg once daily improve renal and cardiovascular surrogate markers in patients with Type 2 diabetes mellitus and chronic kidney disease?
Observational (n=60)
No
Does dapagliflozin 10 mg once daily improve renal and cardiovascular surrogate markers in patients with Type 2 diabetes mellitus and chronic kidney disease?
Absolute Event Rate: 379.5% vs 509.97%
p-value: p=0.0001
In a real-world prospective cohort, adding dapagliflozin to standard therapy for patients with T2DM and CKD significantly improved glycemic control, stabilized eGFR, and reduced UACR and blood pressure over 12 months.
May support cardiorenal benefits of dapagliflozin in T2DM-CKD; hypothesis-generating and requires randomized confirmation before practice change.
Background:Type 2 diabetes mellitus (T2DM) is a major cause of chronic kidney disease (CKD) and cardiovascular morbidity worldwide. Despite adequate glycemic control, many patients continue to experience progressive renal dysfunction and adverse cardiovascular outcomes. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has demonstrated significant cardiorenal protective effects beyond glucose lowering.Aim:To evaluate the cardiovascular and renal outcomes of dapagliflozin in patients with Type 2 diabetes mellitus and chronic kidney disease.Methodology:This prospective observational comparative study was conducted in the Department of General Medicine at Sree MookambikaInstitute of Medical Sciences from November 2024 to December 2025. A total of 60 patients with T2DM and CKD were enrolled and divided into two groups. Group A received dapagliflozin 10 mg once daily along with standard therapy, while Group B received standard therapy alone. Renal and cardiovascular parameters including glycated hemoglobin (HbA1c), fasting blood sugar (FBS), body weight, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), and blood pressure were assessedat baseline, 3 months, 6 months, and 12 months. Statistical analysis was performed using SPSS version 25.0, and a p-value <0.05 was considered statistically significant.Results:Patients receiving dapagliflozin demonstrated significant improvement in glycemic control, renal parameters, and cardiovascular risk factors compared to the control group. HbA1c levels significantly decreased in Group A at 12 months (7.6±0.25 vs 7.91±0.21; p=0.0001). Significant reductions in fasting blood sugar and body weight were also observed. Renal outcomes showed stabilization of eGFR and significant reduction in UACR in the dapagliflozin group, whereas worsening albuminuria was observed in the control group. Improvement in systolic blood pressure was also noted among patients receiving dapagliflozin. Adverse drug reactions such as urinary tract infection and genital infections were more common in the dapagliflozin group, but most were mild and manageable.Conclusion:Dapagliflozin significantly improved glycemic control and provided substantial renal and cardiovascular benefits in patients with Type 2 diabetes mellitus and chronic kidney disease. The drug was generally well tolerated, with mild adverse effects. These findings support the use of dapagliflozin as an effective therapeutic option for improving cardiorenal outcomes in patients with T2DM and CKD.
No takes yet. Share an insight, caveat, or question.
R et al. (2026) conducted an observational in Type 2 diabetes mellitus and chronic kidney disease (n=60). Dapagliflozin vs. Standard therapy alone was evaluated on Urinary albumin-to-creatinine ratio (UACR) at 12 months (p=0.0001). Dapagliflozin significantly improved estimated glomerular filtration rate (53.7 vs 49.7 mL/min/1.73 m²) and reduced urinary albumin-to-creatinine ratio (379.5 vs 509.97 mg/g) at 12 months compared to standard therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: